Kamyar Kalantar-Zadeh

Summary

Affiliation: University of California
Country: USA

Publications

  1. Kalantar Zadeh K. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint. Diabetes Care. 2012;35:1625-8 pubmed publisher
    ..In the counterpoint narrative below, Dr. Kalantar-Zadeh defends the use of A1C as the unquestioned gold standard for glycemic management in dialysis subjects. ..
  2. Kalantar Zadeh K, Shah A, Duong U, Hechter R, Dukkipati R, Kovesdy C. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;:S10-21 pubmed publisher
  3. Kalantar Zadeh K, Regidor D, Kovesdy C, Van Wyck D, Bunnapradist S, Horwich T, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671-9 pubmed publisher
    ..The mechanisms by which fluid retention influences cardiovascular survival in hemodialysis may be similar to those in patients with heart failure and warrant further research. ..
  4. request reprint
    Kalantar Zadeh K, Brennan M, Hazen S. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:59-68 pubmed
    ..82 (95% CI, 1.07 to 3.10; P = 0.03). Serum MPO levels correlate with levels of markers of inflammation and prospective mortality risk in MHD patients. ..
  5. Kalantar Zadeh K, Streja E, Miller J, Nissenson A. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?. Adv Chronic Kidney Dis. 2009;16:143-51 pubmed publisher
  6. Kalantar Zadeh K, Kovesdy C. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529-39 pubmed publisher
    ..Randomized controlled trials are needed to verify which agents offer superior survival advantages. ..
  7. Kalantar Zadeh K, Streja E, Kovesdy C, Oreopoulos A, Noori N, Jing J, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc. 2010;85:991-1001 pubmed publisher
    ..A discordant muscle gain with weight loss over time may confer more survival benefit than weight gain while losing muscle. Controlled trials of muscle-gaining interventions in patients receiving HD are warranted. ..
  8. Feroze U, Kalantar Zadeh K, Sterling K, Molnar M, Noori N, Benner D, et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr. 2012;22:317-26 pubmed publisher
    ..Moderately high endotoxin levels tended to correlate with increased mortality than the highest circulating endotoxin level. Additional studies are required to assess the effect of endotoxemia on mortality in dialysis population. ..
  9. Kalantar Zadeh K, Aronoff G. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol. 2009;20:479-87 pubmed publisher
    ..Strategies that consider each of these factors and reduce hemoglobin variability may be associated with improved clinical outcomes. ..

More Information

Publications16

  1. Kalantar Zadeh K, Lee G, Miller J, Streja E, Jing J, Robertson J, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53:823-34 pubmed publisher
    ..In long-term HD patients, low iron stores, hyperparathyroidism, and high-turnover bone disease are associated with significant ESA hyporesponsiveness. Prospective studies are needed to verify these associations. ..
  2. Kovesdy C, Kalantar Zadeh K. Back to the future: restricted protein intake for conservative management of CKD, triple goals of renoprotection, uremia mitigation, and nutritional health. Int Urol Nephrol. 2016;48:725-9 pubmed publisher
    ..For the time being we recommend a DPI of 0.6-0.8 g/kgBW/day, and increasing this as needed on an individual basis in patients with PEW. Further examination of this dilemma in randomized controlled clinical trials will be necessary. ..
  3. request reprint
    Kalantar Zadeh K, Abbott K, Kronenberg F, Anker S, Horwich T, Fonarow G. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol. 2006;26:118-33 pubmed
  4. request reprint
    Kalantar zadeh K, Kuwae N, Regidor D, Kovesdy C, Kilpatrick R, Shinaberger C, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771-80 pubmed
  5. Park J, Ahmadi S, Streja E, Molnar M, Flegal K, Gillen D, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2014;56:415-25 pubmed publisher
    ..These could include controlled trials of nutritional and pharmacologic interventions to examine whether gain in lean body mass or even body fat can improve survival and quality of life in these patients. ..
  6. request reprint
    Kalantar Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr. 2005;15:318-31 pubmed
    ..8 g/dL, a marker of malnutrition-inflammation complex syndrome, is observed in approximately half of all maintenance hemodialysis (MHD) patients in the United States and is strongly associated with increased mortality...
  7. Kalantar Zadeh K, Gutekunst L, Mehrotra R, Kovesdy C, Bross R, Shinaberger C, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:519-30 pubmed publisher
    ..Provision of in-center and monitored meals during hemodialysis treatment sessions in the dialysis clinic may facilitate the achievement of these goals...